10-K · February 24, 2026
Sotera Health (SHC) presents a business built on vertically integrated sterilization (Sterigenics + Nordion) and lab testing (Nelson Labs) with durable contract coverage and a global facility footprint. Fiscal 2025…
Earnings analysis · 10-Q
SHC earnings analysis
Filed May 5, 2026 · Our reading of the company's report
The latest report
Sotera Health reported strong Q1 2026 results with revenues of $280.0 million, a 10.0% year-over-year increase, and earnings per share (EPS) of $0.18, beating estimates. The Nordion segment significantly contributed to…
Read full summary
Sotera Health reported strong Q1 2026 results with revenues of $280.0 million, a 10.0% year-over-year increase, and earnings per share (EPS) of $0.18, beating estimates. The Nordion segment significantly contributed to revenue growth, while management maintains a favorable outlook for the year, reaffirming their full-year guidance for revenue and EBITDA growth between 5.0%-6.5% and 5.5%-7.0%, respectively.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.18
- Segment
- Sterigenics
- Segment
- Nordion
- Segment
- Nelson Labs
What stood out
-
Strong Revenue Growth
Q1 2026 revenues increased by $25.5 million, or 10.0%, to $280.0 million compared to $254.5 million in Q1 2025.
-
Positive EPS Surprise
Earnings per share for Q1 2026 were reported at $0.18, exceeding the estimate of $0.17 by 5.88%.
-
Nordion Segment Surge
Nordion segment revenues rose by 29.0% to $42.0 million, driven by favorable Co-60 harvest schedules.
-
Improved Net Income
Net income improved to $26.6 million from a loss of $13.3 million in Q1 2025, marking a 300.5% increase.
-
Adjusted EBITDA Growth
Adjusted EBITDA for Q1 2026 increased to $134.7 million, a 10.5% rise from $121.8 million in Q1 2025.
-
Reinforced Guidance
Management reaffirmed full-year revenue growth guidance of 5.0%-6.5%, pointing to sustained operational momentum.
What to watch
-
Increased Litigation Costs
The $30.9 million payment for settling Illinois EO litigation impacts liquidity and may lead to further legal expenses.
-
Interest Rate Exposure
Rising interest rates could affect cash flows and financing costs, with a current average rate of 6.62% on existing debt.
-
Revenues from Product Segment
A decline in Nelson Labs revenue of 0.7% was noted, indicating potential challenges in that segment's performance.
Management's outlook
Management anticipates continued growth in the range of 5.0% to 6.5% for overall revenue for the full year.
Earlier filings 4
10-Q · November 4, 2025
Sotera reported Q3 2025 revenue of $311.3M and diluted EPS of $0.17, driven by Sterigenics and Nordion growth while Nelson Labs declined. Gross margin expanded to 57.0% and operating margin widened to 35.7%…
10-Q · May 1, 2025
Sotera Health reported Q1 revenue of $254,523,000 (up $6,347,000 vs. Q1 2024) with gross margin of 53.2% and a diluted loss per share of $(0.05). Operating margin compressed to 10.3% largely due to a $30,943,000…
10-K · February 27, 2025
Sotera Health (SHC) describes a stable, recurring-revenue sterilization and lab-testing platform anchored by Sterigenics, Nordion and Nelson Labs. The company reported Q4 revenue of $290,203,000 and diluted EPS of $0.21…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.